Key facts
- It has raised $15.0M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Guangdong Yuecai Venture Capital, Fuho Capital, Zhongshan Xiwan Investment Holding Development, Hengbang Capital, Shaanxi Tour Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for GeneBioHealth
- ·The full record, as it builds
Funding rounds
No funding rounds for GeneBioHealth are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GeneBioHealth
Provider of in vitro diagnostic and health-focused biotechnology services intended for supporting early detection and clinical testing. The company offers research and development capabilities, controlled manufacturing, diagnostic reagent and instrument production, clinical laboratory services, and health-related testing support, enabling medical professionals, clinical laboratories, and healthcare institutions to enhance patient care outcomes across preventive and clinical settings.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2013
- Employees
- 57
- Website
- genebiohealth.com/
- Ownership
- Privately Held (backing)
GeneBioHealth doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GeneBioHealth shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GeneBioHealth in its N-PORT filings yet. We sweep new filings monthly.